Cystic fibrosis is an autosomal recessive multisystem progressive disorder that results in mucus in various organs becoming thick and sticky. The disease primarily affects patients’ upper and lower airways, causes long-lasting lung infections, and limits the ability to breathe over time. Dornase alfa is an inhaled medication that thins mucus, used to manage and treat cystic fibrosis. It has been shown to decrease respiratory tract infections in selected patients with forced vital capacity (FVC) greater than 40% of predicted. This activity outlines the indications, action, and contraindications for dornase alfa as a valuable agent in the therapy for cystic fibrosis, pleural effusion, and emphysema.
- Provider:StatPearls, LLC
- Activity Link: https://www.statpearls.com/ArticleLibrary/viewarticle/20665
- Start Date: 2023-09-01 05:00:00
- End Date: 2023-09-01 05:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 1.0 hours
Nursing: 1.0 hours
Pharmacy: 1.0 hours - MOC Credit Details: ABS - 1.0 Point; Credit Type(s): Accredited CME (ABS)
ABPATH - 1.0 Point; Credit Type(s): Lifelong Learning (ABPATH)
ABA - 1.0 Point; Credit Type(s): Lifelong Learning (ABA)
ABIM - 1.0 Point; Credit Type(s): Medical Knowledge (ABIM)
ABS - 1.0 Point; Credit Type(s): Self-Assessment (ABS)
ABP - 1.0 Point; Credit Type(s): Lifelong Learning and Self-Assessment (ABP) - Commercial Support: No
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: Variable
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: Adolescent Medicine, Chemical Pathology, Critical Care Medicine, General Operative Anesthesia, General Pediatrics, General Surgery, Hospital Medicine, Internal Medicine, Molecular Genetic Pathology, Neonatal-Perinatal Medicine, Pediatric Anesthesia, Pediatric Critical Care Medicine, Pediatric Emergency Medicine, Pediatric Pulmonology, Pulmonary Disease
Subscribe
Login
0 Comments
Oldest